Novartis lost 13.54% in the week to Friday 11 September, the worst weekly performance among tracked large-cap stocks, after two late-stage trial failures in four days, and Novo Nordisk fell 7.51% in a week that began with two halted heart-drug trials. Brent crude jumped 8.65% to $104.61 a barrel after Houthi attacks on Saudi oil sites, lifting BP and TotalEnergies, and the European Central Bank raised rates for the second time this year. The STOXX 600 fell 1.66%.
Novartis: Two Trial Misses in Four Days
Novartis closed the week at CHF 112.04. Most of the damage came on Tuesday, when the shares fell 10.89%, their worst day on record, after the Phase III HARBOR trial of del-desiran missed its primary endpoint. The drug, for myotonic dystrophy type 1, was tested in about 150 patients over 54 weeks and did not significantly improve hand opening time against placebo.
Del-desiran was the most advanced asset from Novartis's roughly $12bn takeover of Avidity Biosciences, completed in February. James Eugene of Verso Investment Management was quoted by TIKR as saying the setback would have dented confidence in the company's acquisition strategy.
The miss followed the failure of the heart drug pelacarsen, developed with Ionis, to cut cardiovascular events in the Lp(a)HORIZON study, reported on 4 September. The shares had already fallen 3.18% on Monday.
In New York, the US-listed shares fell 14% on Tuesday, the first trading day after Labor Day, wiping out more than $42bn of market value, BioCentury reported. Dyne Therapeutics, which is developing a rival treatment for the same disease, fell as much as 22%, according to TIKR.
Novartis kept its target of 5% to 6% average annual sales growth from 2025 to 2030 and is reviewing the full HARBOR dataset before talking to regulators.

Novartis: share price, chart and news
Novo Nordisk, Inditex and Adyen Also Slide
Novo Nordisk fell 7.51% to DKK 276.45. On Monday the Danish drugmaker said it had stopped two late-stage heart-failure trials of its drug ziltivekimab early, after an independent monitoring committee saw a low likelihood that either would beat an earlier failed study, Reuters reported. Another trial, in patients recovering from a heart attack, continues, with results due in the first half of 2027.
Inditex fell 5.95% to €54.02. The Zara owner slid as much as 4% on Wednesday after its results disappointed, with rising costs squeezing margins, XTB reported. It closed that day down 3.61%.
Payments group Adyen fell 9.54% to €928.70, losing ground in four of the five sessions. No company-specific trigger was confirmed.
Oil Above $100 Lifts the Energy Majors
Brent settled up 0.9% at $97.92 on Tuesday, its highest close since 23 July, after Iran-backed Houthis attacked four cities in southern Saudi Arabia and set oil installations on fire, Reuters reported. The attacks threatened the Red Sea route Saudi Arabia uses to ship crude around the blocked Strait of Hormuz.
On Wednesday escalating exchanges of fire between the US and Iran, including US strikes on Iranian tankers, pushed European indices down about 1% and Brent back to $100, XTB reported. Brent jumped 6.34% to $107.63 on Thursday, then fell 2.81% on Friday on a report that Gulf foreign ministers could meet Iranian counterparts to discuss shipping arrangements in the Strait of Hormuz.
Energy was the best-performing UK sector of the week as oil climbed above $100, according to Reuters. BP rose 4.61%, TotalEnergies 3.51% and Shell 3.32%.
Chipmakers had a choppy week. Infineon jumped 6.91% on Monday on strong signals from Korean chipmakers, Trading Economics reported, then fell on Wednesday along with ASML after a Morgan Stanley report on European semiconductors. It still ended the week up 2.99%. Nokia rose 10.42% to €9.56 without a confirmed company trigger.
The ECB Hikes and Bund Yields Hit a 2009 High
The ECB raised its rates by 25 basis points on Thursday and warned that inflation could stay well above its 2% target for an extended period. President Christine Lagarde called the move a "no-brainer". Germany's 10-year Bund yield rose above 3.5%, its highest since August 2009, and markets priced three more ECB hikes by March, Trading Economics reported.
Among other heavy fallers, Munich Re lost 4.59% after an insurance sell-off on Monday, and SAP fell 4.53%. London's FTSE 100 lost 1.67%, its biggest weekly fall since late July, although banks led a Friday rebound. Italy's FTSE MIB was the only major European index to rise.
| Index | Close | Week |
|---|---|---|
| Euro Stoxx 50 | 6,325.13 | -1.06% |
| STOXX 600 | 639.10 | -1.66% |
| DAX | 25,568.56 | -1.83% |
| CAC 40 | 8,179.77 | -1.20% |
| FTSE 100 | 10,650.40 | -1.67% |
| FTSE MIB | 52,512.00 | +0.79% |
| IBEX 35 | 19,838.50 | -1.06% |
| S&P 500 | 7,656.98 | -0.80% |
| Nasdaq 100 | 29,368.44 | -0.59% |
Winners and Losers
| Stock | Week | Close |
|---|---|---|
| Nokia | +10.42% | €9.56 |
| AMD | +8.07% | $516.13 |
| Meta | +5.07% | $648.03 |
| Novartis | -13.54% | CHF 112.04 |
| Adyen | -9.54% | €928.70 |
| Novo Nordisk | -7.51% | DKK 276.45 |
Next week the focus moves to Washington. Faster US consumer inflation in August reinforced expectations that the Federal Reserve will raise rates at its meeting next week, Reuters reported. In oil, traders will watch whether talks between Gulf states and Iran on Hormuz shipping go ahead. For Novartis, the next test is what the full HARBOR data and regulators say about del-desiran's future.
Sources
- XTB: Novartis shares fall the most since 2020. What is behind the 10% decline?
- BioCentury: Novartis' Phase III misses compound Novo's cardiovascular setback
- TIKR: Novartis Stock Crashed 11% on Tuesday. Two Failed Trials Are to Blame.
- Reuters via Euronext: Novo scraps two more heart drug trials, further dimming growth beyond obesity
- Reuters via Euronext: Oil prices hit six-week high after Houthis attack Saudi sites
- XTB: Market Wrap: A sunk tanker drags European stocks lower
- Trading Economics: European Stocks Close Muted
- Trading Economics: Eurozone Bond Yields Rise as ECB Rate Hike Bets Grow
- Reuters via Euronext: London shares trim weekly losses after boost from banks
- BMK News market data (delayed exchange data)








